Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) CEO Wenbin Jiang sold 20,000 shares of Cytek Biosciences stock in a transaction on Monday, May 9th. The stock was sold at an average price of $8.01, for a total value of $160,200.00. Following the completion of the sale, the chief executive officer now directly owns 7,896,040 shares of the company’s stock, valued at approximately $63,247,280.40. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Wenbin Jiang also recently made the following trade(s):
- On Thursday, April 7th, Wenbin Jiang sold 20,000 shares of Cytek Biosciences stock. The stock was sold at an average price of $10.54, for a total value of $210,800.00.
- On Monday, March 7th, Wenbin Jiang sold 20,000 shares of Cytek Biosciences stock. The stock was sold at an average price of $12.65, for a total value of $253,000.00.
Shares of CTKB traded up $0.78 during trading hours on Thursday, hitting $8.19. The stock had a trading volume of 23,042 shares, compared to its average volume of 972,634. Cytek Biosciences, Inc. has a 12 month low of $7.38 and a 12 month high of $28.70. The stock has a fifty day moving average price of $10.61 and a 200 day moving average price of $15.09.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CTKB. SG Americas Securities LLC purchased a new position in Cytek Biosciences during the third quarter valued at $148,000. New York State Common Retirement Fund purchased a new position in shares of Cytek Biosciences in the third quarter valued at about $120,000. Deutsche Bank AG purchased a new position in shares of Cytek Biosciences in the third quarter valued at about $212,000. BlackRock Inc. purchased a new position in shares of Cytek Biosciences in the third quarter valued at about $39,711,000. Finally, Citigroup Inc. purchased a new position in shares of Cytek Biosciences in the third quarter valued at about $48,000. Institutional investors own 35.95% of the company’s stock.
CTKB has been the subject of a number of research analyst reports. Morgan Stanley reduced their target price on Cytek Biosciences from $27.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, February 15th. The Goldman Sachs Group cut their price objective on Cytek Biosciences from $28.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, April 13th. Piper Sandler cut their price objective on Cytek Biosciences from $20.00 to $17.00 in a report on Tuesday, March 1st. Finally, Zacks Investment Research lowered Cytek Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, April 28th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $17.00.
Cytek Biosciences Company Profile (Get Rating)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wolverine Worldwide Is Ready To Rebound
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.